Conflict of Interest Information: Bruce Strober has been a principal investigator, an advisor or consultant, or a speaker for the following groups: Abbott, Amgen, Celgene, Janssen, Maruho, Novartis, Pfizer and UBC.
Treatment of atopic dermatitis in pregnancy
Article first published online: 5 AUG 2013
© 2013 Wiley Periodicals, Inc.
Special Issue: Treatment of Cutaneous Disorders of Pregnancy
Volume 26, Issue 4, pages 293–301, July/August 2013
How to Cite
Babalola, O. and Strober, B. E. (2013), Treatment of atopic dermatitis in pregnancy. Dermatologic Therapy, 26: 293–301. doi: 10.1111/dth.12074
- Issue published online: 5 AUG 2013
- Article first published online: 5 AUG 2013
- atopic dermatitis;
- medication safety;
Atopic dermatitis (AD), also referred to as eczema, is one of the most frequently observed skin diseases in pregnant patients. The presentation and histopathology of this condition during pregnancy is identical to that of the non-pregnant individual. AD is a T-helper 2 dominant disease and may worsen during pregnancy, which favors this population of T-lymphocytes. AD management during pregnancy requires special precautions to avoid harming the fetus. Herein is an exploration of the different options available for the treatment of the pregnant patient with AD. The management of concomitant bacterial and viral infections is also discussed.